Viktor Janicki has been elected president of INFARMA's board of directors

On June 12, 2025, during the General Meeting of the Association of Employers of Innovative Pharmaceutical Companies INFARMA, a new Board of Directors and Supervisory Board were elected for another 3-year term. Wiktor Janicki, President of the Management Board of AstraZeneca Pharma Poland, was appointed Chairman of the Board of INFARMA.

Viktor Janicki has been involved in the pharmaceutical industry for 20 years. He joined the sector in 2003 as a financial analyst and held increasingly responsible positions in the industry until he became the CFO of Wyeth in the Czech Republic and Slovakia. In 2010, he returned to Poland and joined Roche as CFO, before becoming CEO of Roche Poland in 2015. In May 2021, he joined AstraZeneca Pharma Poland as CEO. As an experienced manager, he firmly believes that values and true partnerships drive sustainable business. That's why he is passionately committed to building public-private partnerships to build trust and evolve the healthcare system to become even more patient-centered. One of his goals is for the innovative pharmaceutical industry to play an active, important role in raising the standards of health care in Poland. Guided by the motto that "the function of leadership is to inspire more leaders, not more followers," Wiktor Janicki is committed to developing future generations of entrepreneurs.

Wiktor Janicki, as INFARMA's newly-elected CEO, takes the helm at an important moment for the industry, with the public consultation of amendments to the reimbursement law and the final stage of the EU legislative process for the first reform of EU pharmaceutical law in 20 years, which will affect Europe's competitiveness and the future of the innovative pharmaceutical industry for decades to come.

- This is a great honor and proof of trust for me, for which I thank all the members of the Board of Directors and INFARMA's member companies. There are many challenges ahead of us that will affect not only the development of our industry, but also the competitiveness of Europe and the health security of Europeans. As an industry, we want to make Europe the place again for research, development and production of new diagnostics, therapies and vaccines. And we are constantly working on this. I am therefore extremely looking forward to our work together, firmly believing that it is the innovation industry that plays a key role in the public debate, shaping a strong and stable health care sector in our country and in Europe, with a real impact on improving Polish patients' access to the latest therapies, and consequently on their health, quality of life and safety," said Wiktor Janicki, INFARMA's CEO. - At the same time, I would like to thank Phil, as outgoing President, for his commitment and significant contribution to building dialogue under the Polish Presidency, whose both legislative and health priorities have contributed to increasing the role of education and awareness of the value of prevention, digitization or mental health of children and adolescents," he stressed.

Phil Krzyzek, as Managing Director at Merck Sp. z o.o., took over as President of INFARMA in December 2024 and held the position until the end of the Board's 3rd term in June this year, during the exceptional period of the Polish Presidency of the Council of the EU.

- It has been a great honor for me to serve as INFARMA's president over the past months. At a time of many new geopolitical challenges, the Polish presidency of the Council of the EU has become even more important by accurately identifying priorities and elevating health to one of the 7 pillars of security. I believe that this will ensure that further dialogue on health security will take place in an atmosphere of understanding that health is an investment in the health of populations, the efficiency of health systems and the development of the economy. I am pleased to have been a participant in the dialogue on this topic, and I am convinced that our industry will continue to be an important partner in the process of building a competitive and health-secure Europe. I thank everyone for their cooperation and wish good luck to the new President and Board of Directors," Phil Krzyzek stressed.

Delegates at the General Assembly also elected members of the Board of Directors and the composition of the Supervisory Board of the Union of Employers of Innovative Pharmaceutical Companies INFARMA.

Board members